GORDON RESEARCH CONFERENCE ON KALLIKREINS AND KININS
激肽释放酶和激肽戈登研究会议
基本信息
- 批准号:3435588
- 负责人:
- 金额:$ 1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1986
- 资助国家:美国
- 起止时间:1986-02-01 至 1987-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Kallikreins and kininogenases (kinin-generating enzymes) are serine
proteases with limited and specific proteolytic capability. The existence
of a large kallikrein gene family (announced at the last Gordon
Conference); the diversity of localization sites including: plasma, sperm,
peripheral exocrine glands and their secretions, renal and intestinal
epithelial cells, various brain nucleii, pituitary and pineal, red blood
cell membrane and other formed elements of blood, the vascular wall, as
well as closely related enzymes in invertebrates and bacteria; the
possibility that the "kallikrein-kinin" system is but a paradigm for many
other kallikrein-regulated, substrate-product systems because tissue
kallikreins can attack several newly identified substrates, (e.g., atrial
natriuretic factor precursors, apolipoprotein B100); are all reasons for a
markedly heightened interest since the 1983 Gordon Conference.
It is now being suggested that the tissue kallikrein gene family may be
responsible for the synthesis of several closely-related kallikreins with
diverse, but bond-specific proteolytic activities which regulate the
elaboration of many peptide hormones. This exciting idea is being tempered
by the realization that there is, as yet, no proof that tissue kallikreins
act upon any endogenous substrates, other than kininogens. Data are being
gathered in many laboratories which addresses this issue, most important to
the full description of the functional responsibilities of the kallikreins
and of the kinins. A family of long-awaited and newly synthesized kinin
antagonists are beginning to be used in these tasks. In addition, other
recent advances in the study of kallikreins and kinins have been made using
state-of-the-art technologies in molecular genetics and biology,
biophysics, synthetic and organo-analytical chemistry, and immunology.
Thus, the study of kallikreins and kinins has reached a most exciting point
with health-related implications to cardiovascular, metabolic,
endocrinologic, inflammatory and malignant diseases. The purpose of this
proposal is to request funds to further facilitate these studies by
partially supporting the third Gordon Research Conference on Kallikreins
and Kinins. This conference, as its predecessors, will serve to further
stimulate both new and established investigators to new discovery in this
area of endeavor.
激肽释放酶和激肽原酶(产生激肽的酶)是丝氨酸
具有有限和特异性蛋白水解能力的蛋白酶。 存在
一个大的激肽释放酶基因家族(在去年的戈登
会议);定位位点的多样性,包括:血浆,精子,
外周外分泌腺及其分泌物,肾和肠
上皮细胞,各种脑细胞核,垂体和松果体,红血
细胞膜和其他血液成分,血管壁,如
以及无脊椎动物和细菌中密切相关的酶;
“激肽释放酶-激肽”系统只是许多人的范例的可能性
其他激肽释放酶调节的底物产物系统,因为组织
激肽释放酶可以攻击几种新鉴定的底物,(例如,心房
利钠因子前体,载脂蛋白B100);都是
自1983年戈登会议以来,人们的兴趣明显提高。
现在有人提出,组织激肽释放酶基因家族可能是
负责合成几种密切相关的激肽释放酶,
不同的,但键特异性的蛋白水解活性,调节
许多肽激素的加工。 这个令人兴奋的想法正在酝酿
到目前为止,还没有证据表明组织激肽释放酶
作用于除激肽原以外的任何内源性底物。 数据正在
在许多实验室聚集,解决这个问题,最重要的是,
激肽释放酶功能职责的完整描述
和激肽的关系 一个期待已久的新合成的激肽家族
在这些任务中开始使用拮抗剂。 此外,其他
在激肽释放酶和激肽的研究中已经取得了最新进展,
最先进的分子遗传学和生物学技术,
生物物理学、合成和有机分析化学以及免疫学。
因此,激肽释放酶和激肽的研究已经达到了一个最令人兴奋的点
对心血管,代谢,
内分泌、炎症和恶性疾病。 这样做的目的
建议要求资金,以进一步促进这些研究,
部分支持第三届戈登激肽释放酶研究会议
还有Kinins 本次会议,作为其前身,将进一步
刺激新的和建立的研究人员在这方面的新发现,
奋进的领域。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HARRY S MARGOLIUS其他文献
HARRY S MARGOLIUS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HARRY S MARGOLIUS', 18)}}的其他基金
相似海外基金
Potential of tissue kallikreins as therapeutic targets for neuropsychiatric lupus
组织激肽释放酶作为神经精神狼疮治疗靶点的潜力
- 批准号:
10667764 - 财政年份:2023
- 资助金额:
$ 1万 - 项目类别:
Unlocking the mechanism of kallikreins modulating the adhesion of prostate cancer cells to bone
解开激肽释放酶调节前列腺癌细胞与骨粘附的机制
- 批准号:
166524083 - 财政年份:2010
- 资助金额:
$ 1万 - 项目类别:
Research Fellowships
Regulation and Function of Kallikreins in Spinal Cord Injury and Repair
激肽释放酶在脊髓损伤和修复中的调节和功能
- 批准号:
8039171 - 财政年份:2008
- 资助金额:
$ 1万 - 项目类别:
Regulation and Function of Kallikreins in Spinal Cord Injury and Repair
激肽释放酶在脊髓损伤和修复中的调节和功能
- 批准号:
7456686 - 财政年份:2008
- 资助金额:
$ 1万 - 项目类别:
Long-term prediction of prostate cancer death from kallikreins measured in blood
血液中激肽释放酶对前列腺癌死亡的长期预测
- 批准号:
7387192 - 财政年份:2008
- 资助金额:
$ 1万 - 项目类别:
Long-term prediction of prostate cancer death from kallikreins measured in blood
血液中激肽释放酶对前列腺癌死亡的长期预测
- 批准号:
8118945 - 财政年份:2008
- 资助金额:
$ 1万 - 项目类别:
Regulation and Function of Kallikreins in Spinal Cord Injury and Repair
激肽释放酶在脊髓损伤和修复中的调节和功能
- 批准号:
7597052 - 财政年份:2008
- 资助金额:
$ 1万 - 项目类别:
Long-term prediction of prostate cancer death from kallikreins measured in blood
血液中激肽释放酶对前列腺癌死亡的长期预测
- 批准号:
8100765 - 财政年份:2008
- 资助金额:
$ 1万 - 项目类别: